Business Description
TME Pharma NV
ISIN : NL0015000YE1
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.93 | |||||
Equity-to-Asset | -0.12 | |||||
Debt-to-Equity | -3.97 | |||||
Debt-to-EBITDA | -0.23 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 59.1 | |||||
3-Year EPS without NRI Growth Rate | 64.1 | |||||
3-Year FCF Growth Rate | 57.6 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.5 | |||||
9-Day RSI | 49.23 | |||||
14-Day RSI | 46.94 | |||||
6-1 Month Momentum % | -28.66 | |||||
12-1 Month Momentum % | -85.35 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.86 | |||||
Quick Ratio | 0.86 | |||||
Cash Ratio | 0.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -221.6 | |||||
Shareholder Yield % | -14.71 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -180.53 | |||||
ROIC % | -178.75 | |||||
ROC (Joel Greenblatt) % | -3266.81 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.16 | |||||
EV-to-EBITDA | -1.19 | |||||
EV-to-FCF | -1.07 | |||||
Earnings Yield (Greenblatt) % | -86.21 | |||||
FCF Yield % | -79.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
TME Pharma NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.34 | ||
Beta | 1.09 | ||
Volatility % | 89.3 | ||
14-Day RSI | 46.94 | ||
14-Day ATR (€) | 0.017204 | ||
20-Day SMA (€) | 0.250025 | ||
12-1 Month Momentum % | -85.35 | ||
52-Week Range (€) | 0.1902 - 1.985153 | ||
Shares Outstanding (Mil) | 28.42 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TME Pharma NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TME Pharma NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
TME Pharma NV Frequently Asked Questions
What is TME Pharma NV(XPAR:ALTME)'s stock price today?
When is next earnings date of TME Pharma NV(XPAR:ALTME)?
Does TME Pharma NV(XPAR:ALTME) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |